4.6 Article

A Novel Biological Strategy for Myocardial Protection by Intracoronary Delivery of Mitochondria: Safety and Efficacy

Journal

JACC-BASIC TO TRANSLATIONAL SCIENCE
Volume 4, Issue 8, Pages 871-888

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacbts.2019.08.007

Keywords

ischemia-reperfusion injury; mitochondria; mitochondrial transplantation; myocardial protection

Funding

  1. Richard A. and Susan F. Smith President's Innovation Award
  2. Sidman Family Foundation
  3. Michael B. Rukin Charitable Foundation
  4. Kenneth C. Griffin Charitable Research Fund
  5. Boston Investment Conference
  6. National Institutes of Health (NIH) [5T32HL007734]
  7. NIH [5 RO1 HL108107]

Ask authors/readers for more resources

Mitochondrial dysfunction is the determinant insult of ischemia-reperfusion injury. Autologous mitochondrial transplantation involves supplying one's healthy mitochondria to the ischemic region harboring damaged mitochondria. The authors used in vivo swine to show that mitochondrial transplantation in the heart by intracoronary delivery is safe, with specific distribution to the heart, and results in significant increase in coronary blood flow, which requires intact mitochondrial viability, adenosine triphosphate production, and, in part, the activation of vascular Km channels. Intracoronary mitochondrial delivery after temporary regional ischemia significantly improved myocardial function, perfusion, and infarct size. The authors concluded that intracoronary delivery of mitochondria is safe and efficacious therapy for myocardial ischemia-reperfusion injury. (C) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available